A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
This research study is studying a targeted therapy as a possible treatment for multiple
myeloma.
The names of the study drugs involved in this study are:
- Trametinib
- Dabrafenib
Phase:
Phase 1
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
Barbara Ann Karmanos Cancer Institute Multiple Myeloma Research Consortium Novartis